http___www.klix.ba_lifestyle_zdravlje_lijek-za-rak-pluca-avastin-odobren-u-eu_070905101_1.xml
1.1 1.2 1.3 2.1 3.1 4.1 5.1 5.2 6.1 7.1 7.2 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 17.2 17.3 18.1 19.1 20.1 20.2 21.1 21.2 22.1 23.1 23.2 23.3 24.1 25.1
Small cell lung cancer is fast growing and the most aggressive type of lung cancer that occurs more frequently in men than women. It accounts for approximately 12% of all lung cancers and, in the majority of cases, is the result of smoking. It is quite rare to see patients with small cell lung cancer who have never smoked. There are two types of small cell lung cancer and the cancer cells of each type will spread in different ways: - Small cell carcinoma (also known as oat cell cancer due to the shape of the cancer cells) - Combined small cell carcinoma The disease usually starts in the centre of the chest in the bronchi and spreads widely to lymph nodes and organs such as the bones, brain, liver and adrenal glands. The spread is rapid and often the disease has spread before any noticeable symptoms have been detected. Small cell lung cancer symptoms Because small cell lung cancer spreads so quickly, symptoms may not present until well after the disease has spread to other organs. Small cell lung cancer symptoms may include: - Shortness of breath - Coughing up blood - A persistent cough - Repeated cases of pneumonia or bronchitis - Swelling in the face and neck - Back, rib or hip pain due to spread to the bones - Headaches, vision changes, weakness or seizures due to spread to the brain The fact that this type of lung cancer spreads very rapidly highlights the importance for early detection. Small cell lung cancer treatment As with all lung cancers, the type of treatment for small cell lung cancer will depend on the stage of the disease. The most common forms of small cell lung cancer treatments are chemotherapy and radiotherapy and, if the disease is in the early stages there is a potential for cure. Very often, patients in the early stages who respond well to chemotherapy and radiation therapy may also undergo preventative radiation (prophylactic cranio–irradiation) therapy to the brain as small cell lung cancer cells can often spread to the brain but not be detected. Surgery is very rarely used for small cell lung cancer unless the tumour is detected in the very early stages and there has been no spread outside the lung and nearby lymph nodes. Small cell lung cancer prognosis Survival rates for small cell lung cancer will depend on the stage at which the disease was detected as well as other factors such as general health and gender. Women have improved survival rates over men for this type of lung cancer. The overall survival rate for small cell lung cancer is approximately 6% but please refer to our lung cancer prognosis page for more detailed information about 5-year survival rates for small cell lung cancer at different stages. If the disease is caught at the early stages, 5-year survival rates can be up to 38%. Lung Cancer Screening The rapid spread of small cell lung cancer, often without any recognisable symptoms and the associated decline in 5-year survival rates as the disease progresses really highlights the importance of early detection. The LungCheck lung cancer screening service offered by LungHealth UK is a simple blood test and risk assessment that will help to pick up signs of lung cancer early as well as identify risk factors that can be addressed. If you think you may be suffering symptoms or are at risk then please contact us to arrange an appointment for a LungCheck. More information about lung cancer If you would like further information about lung cancer, please see our lung cancer information page or contact us.
1.1 2.1 3.1 4.1 5.1 6.1 7.1 7.2 8.1 9.1 10.1 11.1 12.1 13.1 14.1 15.1 16.1 17.1 18.1
Lijek za rak pluća Avastin odobren u EU Anti-tumorski lijek Avastin (bevacizumab) odobren je u EU za primjenu u prvoj liniji liječenja oboljelih od uznapredovalog raka pluća ne-malih stanica, u kombinaciji s kemoterapijom, priopćila je danas farmaceutska kuća Roche. Avastin je jedini lijek koji je u kombinaciji s kemoterapijom omogućio preživljavanje bolesnika dulje od godinu dana. Novi lijek sprečava stvaranje tumorskih krvnih žila odgovornih za opskrbu tumora kisikom i hranjivim tvarima. Europsko odobrenje temelji se na pozitivnim rezultatima dviju velikih studija koje su potvrdile bolju učinkovitost Avastina kada se primjenjuje u kombinaciji s kemoterapijom u odnosu na samo kemoterapiju. Po podacima Svjetske zdravstvene organizacije, rak pluća vodeći je uzrok smrti koje se povezuju sa zloćudnim bolestima - njemu se pripisuje 19,7 posto smrti uzrokovanih zloćudnim bolestima. Samo u Europi, lani je od raka pluća umrlo 334.800 osoba. Svake godine se u svijetu otkrije više od 1,2 milijuna novih slučajeva raka pluća i bronha. Rak pluća ne-malih stanica najčešći je oblika raka pluća i javlja se u više od 80 posto slučajeva, a većinom se otkriva tek u uznapredovaloj fazi, kada je neoperabilan i kada se proširio na udaljene organe. Usprkos primjeni kemoterapije kao prve linije liječenja, manje od pet posto oboljelih preživi pet godina od postavljanja dijagnoze, a većina oboljelih umire unutar šest mjeseci. Prethodne vijesti Namirnice sa najviše omega-3 masnih kiselina Porodična terapija u borbi protiv bulimije Nema operacija za gojazne pacijente i pušače Kako doživjeti stotu? Komentari na članak - Ukupno: 1 Svi komentari SVE JE TO SMEĆE OBIČNO!!! SAMO ULJE MARIHUANE LIJEČI RAK.